The composite secondary end point of cardiovascular mortality , MI , and stroke was observed in 107 patients ( 4.6 % ) in the varespladib group and 79 patients ( 3.8 % ) in the placebo group ( HR , 1.36 ; 95 % CI , 1.02-1 .82 ; P = .04 ) .